What's Happening?
The General Pharmaceutical Council (GPhC) has reported its highest ever number of concerns in the second quarter of 2025/2026, with 2,159 issues raised. The concerns primarily relate to customer service issues and dispensing errors, reflecting broader
pressures in the pharmacy sector. A significant portion of these concerns, 15%, are related to weight management medications, particularly following a price increase of Mounjaro (semaglutide) by Eli Lilly. The GPhC has also noted an increase in enforcement actions due to governance issues in several pharmacy businesses, including Jhoots Pharmacy, which is undergoing rebranding to JHL Pharmacy.
Why It's Important?
The surge in concerns highlights the challenges faced by the pharmacy sector, including stock shortages and customer service issues, which can impact public trust and healthcare delivery. The GPhC's increased enforcement actions indicate a stricter regulatory environment, which could lead to improved standards but also increased operational pressures for pharmacies. The focus on weight management medications underscores the growing demand and scrutiny in this area, which could influence future regulatory policies and market dynamics.
What's Next?
The GPhC plans to develop a policy on the disqualification of pharmacy owners, with a draft expected by February 2026. This policy aims to provide clear guidelines on when disqualification proceedings are appropriate, potentially leading to stricter accountability for pharmacy owners. The ongoing issues with Jhoots Pharmacy and the rebranding efforts will be closely watched by stakeholders, as they may signal broader changes in the pharmacy sector's regulatory landscape.
